



14<sup>th</sup> December 2010

**Chair, Podiatry Board of Australia**

**Re: Consultation Paper “Guidelines for Endorsement for Scheduled Medicines”**

The Podiatry Board of Australia recently issued a consultation paper on “Guidelines for Endorsement of Scheduled Medicines”. The South Australian Podiatry Association would like to provide its comments and suggestions in relation to this document.

The South Australian Podiatry Association (APodA SA):

- Supports the Podiatry Board of Australia in the development of the guidelines for the endorsement for scheduled medicines
- Supports the development of a List of Scheduled Medicines approved by the Board (“The National Drug List”) across all jurisdictions
- Supports a consistent standard for endorsement for scheduled medicines across all Australian jurisdictions
- The APodA SA agrees that the development of a consistent list of scheduled medicines across all jurisdictions will provide benefits to patient safety, consistency of practise and a consistent continuum of care for patients across Australia.
- The APodA SA believes that the Podiatry Board of Australia is the most appropriate agency to manage the standards for endorsement and the National Drug List.
- The APodA SA believes that a podiatrist registered as a podiatric surgeon under the National Law requires access to an extended list of drugs specific to the requirements of podiatric surgery.

The APodA SA recommends that the following additional **antibacterial** agents are available to podiatric surgeons by either oral “O” or Intra-venous “IV” route. These recommendations are adopted from the “**Therapeutic Guidelines - Antibiotic**” Version 14 of 2010.

**Benzylpenicillin IV** for surgical prophylaxis in amputation for diabetic patients

**Cefotaxime IV** or **Ceftriaxone IV** for gram-negative osteomyelitis or septic arthritis

**Cephazolin IV** for preoperative prophylaxis and empiric treatment of osteomyelitis in patients who are hypersensitive to penicillin, excluding immediate hypersensitivity

**Vancomycin IV** for preoperative prophylaxis and empiric treatment of osteomyelitis for patients with immediate penicillin hypersensitivity

**Ciprofloxacin IV** for patients with immediate penicillin hypersensitivity with contaminated wounds

**Gentamicin IV** for sepsis due to gram-negative enteric bacteria

**Lincomycin IV** for patients with immediate penicillin hypersensitivity and MSSA with proven macrolide susceptibility

**Piperacillin + tazobactam IV** or **Ticarcillin + clavulanate IV** for open, soiled wounds or infection in the presence of devitalized tissue eg diabetic patients

**Rifampicin + Fusidate O** for treatment of osteomyelitis due to MRSA

The APodA SA recommends that the following additional **analgesic** agents are available to podiatric surgeons. These recommendations are adopted from the “**Therapeutic Guidelines - Analgesic**” Version 5 of 2007.

**Tramadol** IV and O immediate-release and modified-release for reduced incidence and severity of opioid adverse effects eg respiratory depression and constipation plus limited potential for tolerance, physical dependence and addiction, even with long-term use.

**Parecoxib** IV for multimodal analgesia during surgery

**Piroxicam** oral for post-postoperative pain and as an analgesic, especially where there is an inflammatory component.

The APodA SA recommends that the following additional **antithrombotic** agents are available to podiatric surgeons. These recommendations are adopted from the “**Therapeutic Guidelines – Cardiovascular**”, version 5, 2008.

**Enoxaparin** Subcutaneous for perioperative venous thromboembolism prophylaxis

**Dalteparin** Subcutaneous for perioperative venous thromboembolism prophylaxis

The APodA SA recommends that the following additional **antiemetic** agents are available to podiatric surgeons. These recommendations are adopted from the “**Therapeutic Guidelines – Gastrointestinal**” version 4, 2006  
**5-HT<sub>3</sub>-receptor antagonists** are effective at preventing vomiting and have a favourable adverse effect profile.

**Ondansteron** IV for prophylaxis and treatment of postoperative nausea and vomiting

**Dolasetron** IV for prophylaxis and treatment of postoperative nausea and vomiting


**Droperidol** has been shown to be effective when given at the end of anaesthesia

**Promethazine** given at the end of surgery has been shown to be effective in preventing PONV.

The APodA SA encourages individual states to adopt model legislation similar to section 17C of the Poisons and Therapeutics Good Act 1966 No 31 of NSW. This act authorises the possession, use, supply or prescription of substances by a podiatrist and allows the Podiatry Board of Australia to manage the development of guidelines, endorsement process and the National Drug List.

**“A podiatrist whose registration is endorsed under section 94 of the Health Practitioner Regulation National Law as being qualified to possess, use, supply or prescribe a poison or restricted substance is authorised to possess, use, supply or prescribe that poison or restricted substance for the purpose of the practice of podiatry.”**

The APodA SA encourages the Department to consider similar legislative changes when the relevant act is reviewed that will allow the Podiatry Board of Australia to manage the development of guidelines, endorsement process and the National Drug List on behalf of individual states.



On behalf of  
APodA SA Council